Posted on

Human Genomes Shaped by Past Events that Caused Sharp Dips in the Population

587656.jpg
587656.jpg

Representation of the impact of a founder event on genetic data with an initial population made of various genomic segments that were inherited identical-by-descent (IBD) from a common ancestor. Following a founder event, the diversity of IBD segments is reduced and due to recombination events, the length of these IBD segments shortens gradually—these two parameters are thus informative about the founder strength and age, respectively. CREDIT Rémi Tournebize and Priya Moorjani (

The genomes of many human populations show evidence of founder events, which occur when a small number of initial members start a new population, and can lead to low genetic diversity as well as increase the risk of certain genetic diseases in the new population. Rémi Tournebize and Priya Moorjani of the University of California, Berkeley report these new findings in the open access journal PLOS Genetics.

Founder events can occur when a population experiences a sharp decrease in numbers or when a few individuals colonize an isolated environment, such as an island. Despite the large impact that founder events can have on a population’s genetics, we know few details of how these events have shaped the evolution of humans and other species.

To better understand these past events, researchers developed a new technique called ASCEND that uses genomic analysis to estimate the timing and strength of founder events. In the new study, they applied ASCEND to analyze about 460 human populations worldwide. The researchers found that over half of the populations that they analyzed had evidence of recent founder events, including most living hunter-gatherer, nomadic and indigenous groups that were sampled. These founder events are associated with geographic isolation, a hunter-gatherer lifestyle, or the cultural practice of marrying within your own group or religion.

The researchers also analyzed about 200 modern dog populations and found that most populations show signs of extreme founder events. These events occurred within the last 25 generations, coinciding with the start of dog breeding during Victorian times, and may be related to inbreeding and the use of a few highly prized males to sire numerous litters.

The new analysis technique will help scientists to identify groups that experienced strong founder events and that may be at high risk of certain genetic diseases. Ashkenazi Jews and Finns, who experienced strong founder events, often undergo genetic screening to learn about their pre-disposition to certain genetic diseases. The study found that several populations among Native Americans, Oceanians, and South Asians have experienced even more extreme founder events than Ashkenazi Jews, and so these populations may also benefit from genetic screening.

“Some human populations like Ashkenazi Jews or Finns have been extensively studied in population genetics and have helped researchers identify many disease-causing mutations,” say the researchers. “Hence, we wanted to study if other populations have a similar history that could enable further progress in medical genetics. We were surprised to see how widespread the history of founder events is in humans, both in present-day and ancient DNA samples, suggesting that investigation of disease-causing variants will be fruitful to identify and reduce disease burden among contemporary groups.”

Republished courtesy of PLOS. 

 

 

Posted on

Reduced kidney function caused by antithrombotic therapy can influence bleeding events

Reduced kidney function caused by antithrombotic therapy can influence bleeding events

Antithrombotic therapy is prescribed to prevent thrombotic (blood clotting inside a blood vessel) events but the treatment also increases the likelihood of experiencing a bleeding event, which can be extremely serious if it occurs in a vital organ. Aging societies tend to have an increased number of patients undergoing antithrombotic therapy, and the drugs used in this treatment can affect kidney function. In particular, reduced kidney function caused by antithrombotic medications can significantly influence bleeding events. It is highly recommended that patients, especially those with decreased kidney function, have a detailed discussion with their doctor about the possible risks and benefits of proceeding with antithrombotic therapy.

Patients with heart arrythmia (atrial fibrillation) have a high risk for thrombotic events in blood vessels that could lead to permanent organ damage-;such as cerebral infarction-;and are prescribed antithrombotic therapy to lower their risk of developing blood clots. However, the risk of bleeding events simultaneously increases due to the nature of these medications. The severity of these bleeding events is highly variable, ranging from epistaxis (nosebleeds) to fatal brain hemorrhage.

While kidney function is known to be related to bleeding event risk, researchers at Kumamoto, Miyazaki, and Tohoku Universities in Japan conducted a post-hoc subgroup analysis of the Atrial Fibrillation and Ischemic Events with Rivaroxaban in Patients with Stable Coronary Artery Disease (AFIRE) trial to determine the impact of kidney function on the risk of recurrent bleeding events during antithrombotic therapy. Their analysis revealed that the effect of kidney function on recurrent bleeding risk events was quite large for patients undergoing this treatment. They also found that the bleeding risk decreased with time for patients with healthy kidney function but remained high for patients with decreased kidney function. Clearly, the decision to use such a therapy should be balanced between the expected antithrombotic effects and bleeding risks.

In most cases, it is considered better to continue antithrombotic therapies even after bleeding events as long as the event was not severe. However, it is not surprising that both patients and physicians hesitate to continue the therapy after any bleeding event. To assess for drug safety and efficacy, these drugs are usually measured by the numbers of bleeding and thrombotic events. Unfortunately, in the assessment of antithrombotic therapy, most studies only consider the first event in their analyses even though patients could experience multiple events throughout their lifetime. This study revealed that the impact of kidney function on bleeding risk during antithrombotic therapy is larger than estimated in previous studies. Furthermore, patients with healthy kidney function appear to have a decreased risk of experiencing a bleeding event over time, but the risk for patients with reduced kidney function remains high as time continues.

A detailed discussion between patients and physicians based on all current scientific evidence about the risks and benefits of antithrombotic therapy is highly recommended. Our analysis should be quite useful in facilitating this type of discussion.”


Dr. Kunihiko Matsui, Study Leader, Kumamoto University Hospital’s Department of General Medicine and Primary Care

Source:

Journal reference:

Matsui, K., et al. (2022) The impact of kidney function in patients on antithrombotic therapy: a post hoc subgroup analysis focusing on recurrent bleeding events from the AFIRE trial. BMC Medicine. doi.org/10.1186/s12916-022-02268-6.